Newbury Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013 Obs Exp SIR 95% CI Obs Exp SIR 95% CI Bladder, Urinary Melanoma of Skin Male 7 8.7 80.6 (32.3- 166.1) Male 14 5.7 246.5 (134.7- 413.7) Female 3 2.6 nc (nc-nc) Female 2 3.8 nc (nc-nc) Brain and Other Nervous System Multiple Myeloma Male 4 1.6 nc (nc-nc) Male 2 1.8 nc (nc-nc) Female 2 1.2 nc (nc-nc) Female 1 1.2 nc (nc-nc) Breast Non-Hodgkin Lymphoma Male 0 0.3 nc (nc-nc) Male 5 5.0 99.4 (32.0-231.9) Female 36 31.8 113.3 (79.4- 156.9) Female 4 3.8 nc (nc-nc) Cervix Uteri Oral Cavity & Pharynx Male 3 4.3 nc (nc-nc) Female 0 1.0 nc (nc-nc) Female 1 1.6 nc (nc-nc) Colon / Rectum Ovary Male 8 9.5 84.5 (36.4- 166.6) Female 6 7.8 77.2 (28.2- 168.1) Female 3 2.8 nc (nc-nc) Esophagus Pancreas Male 2 2.5 nc (nc-nc) Male 2 3.2 nc (nc-nc) Female 0 0.5 nc (nc-nc) Female 1 2.6 nc (nc-nc) Hodgkin Lymphoma Prostate Male 0 0.6 nc (nc-nc) Male 33 32.9 100.4 (69.1-140.9) Female 0 0.4 nc (nc-nc) Kidney & Renal Pelvis Stomach Male 3 5.0 nc (nc-nc) Male 0 2.1 nc (nc-nc) Female 3 2.5 nc (nc-nc) Female 0 1.0 nc (nc-nc) Larynx Testis Male 2 1.5 nc (nc-nc) Male 0 0.9 nc (nc-nc) Female 0 0.4 nc (nc-nc) Leukemia Thyroid Male 0 3.4 nc (nc-nc) Male 3 2.2 nc (nc-nc) Female 0 2.1 nc (nc-nc) Female 7 5.6 125.5 (50.3-258.7) Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS Male 2 3.3 nc (nc-nc) Female 1 0.9 nc (nc-nc) Female 9 7.5 120.5 (55.0-228.7) Lung and Bronchus All Sites / Types Male 11 16.1 68.2 (34.0- 122.1) Male 109 119.2 91.5 (75.1-110.4) Female 9 15.0 60.2 (27.5- 114.2) Female 95 103.7 91.7 (74.1-112.0) Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100);
66
Embed
Cancer Incidence in Massachusetts 2009-2013: Tables … · Web viewBrain and Other Nervous System Multiple Myeloma Male 4 1.6 nc (nc-nc) Male 2 1.8 nc (nc-nc) Female 2 1.2 nc (nc-nc)
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
NewburyObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 7 8.7 80.6 (32.3-166.1) Male 14 5.7 246.5 (134.7-413.7)Female 3 2.6 nc (nc-nc) Female 2 3.8 nc (nc-nc)
Brain and Other Nervous System Multiple MyelomaMale 4 1.6 nc (nc-nc) Male 2 1.8 nc (nc-nc)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
214
NewburyportObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 19 20.6 92.0 (55.4-143.7) Male 29 13.4 216.3 (144.8-310.7)Female 7 8.4 83.1 (33.3-171.3) Female 18 11.6 155.7 (92.3-246.1)
Brain and Other Nervous System Multiple MyelomaMale 2 3.9 nc (nc-nc) Male 2 4.3 nc (nc-nc)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
215
NewtonObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 88 102.1 86.2 (69.1-106.2) Male 69 62.6 110.3 (85.8-139.6)
Female 46 35.1 130.9 (95.8-174.6) Female 62 48.3 128.4 (98.4-164.6)Brain and Other Nervous System Multiple Myeloma
Male 24 18.0 133.2 (85.3-198.2) Male 26 19.9 130.6 (85.3-191.3)Female 16 15.4 104.0 (59.4-168.9) Female 18 15.7 114.5 (67.8-180.9)
Breast Non-Hodgkin LymphomaMale 3 3.4 nc (nc-nc) Male 61 56.2 108.6 (83.1-139.5)
Male 41 39.5 103.8 (74.5-140.9) Male 34 22.4 152.1 (105.3-212.5)Female 22 28.7 76.6 (48.0-115.9) Female 81 68.0 119.1 (94.6-148.0)
Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOSMale 31 32.8 94.4 (64.1-134.0)
Female 9 11.0 81.5 (37.2-154.7) Female 91 85.7 106.2 (85.5-130.4)Lung and Bronchus All Sites / Types
Male 130 177.9 73.1 (61.0-86.8) Male 1189 1278.0 93.0 (87.8-98.5)Female 158 182.0 86.8 (73.8-101.5) Female 1370 1288.7 106.3 (100.8-112.1)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
216
NorfolkObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 7 11.2 62.3 (24.9-128.3) Male 12 8.5 140.6 (72.6-245.7)Female 2 2.5 nc (nc-nc) Female 7 4.3 161.5 (64.7-332.9)
Brain and Other Nervous System Multiple MyelomaMale 0 2.8 nc (nc-nc) Male 4 2.6 nc (nc-nc)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
217
North AdamsObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 18 17.1 105.4 (62.4-166.5) Male 6 10.4 57.6 (21.0-125.4)Female 12 5.9 202.8 (104.6-354.2) Female 8 7.8 102.5 (44.1-201.9)
Brain and Other Nervous System Multiple MyelomaMale 3 3.0 nc (nc-nc) Male 4 3.3 nc (nc-nc)
Male 6 6.6 90.9 (33.2-197.8) Male 3 3.7 nc (nc-nc)Female 5 4.7 107.0 (34.5-249.7) Female 9 10.7 84.4 (38.5-160.1)
Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOSMale 11 5.2 209.6 (104.5-375.1)
Female 3 1.8 nc (nc-nc) Female 12 13.7 87.9 (45.4-153.6)Lung and Bronchus All Sites / Types
Male 34 29.7 114.5 (79.3-160.0) Male 230 208.2 110.5 (96.7-125.7)Female 47 31.4 149.8 (110.0-199.2) Female 223 210.8 105.8 (92.4-120.6)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
218
North AndoverObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 35 28.9 121.1 (84.3-168.4) Male 18 18.8 95.5 (56.6-151.0)Female 13 11.5 112.7 (59.9-192.7) Female 12 15.7 76.3 (39.4-133.3)
Brain and Other Nervous System Multiple MyelomaMale 6 5.8 102.9 (37.6-224.1) Male 5 5.8 85.5 (27.5-199.5)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
219
North AttleboroughObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 21 23.1 90.7 (56.1-138.7) Male 17 16.3 104.1 (60.6-166.7)Female 7 8.2 85.1 (34.1-175.4) Female 22 13.4 164.2 (102.9-248.6)
Brain and Other Nervous System Multiple MyelomaMale 6 5.5 108.8 (39.7-236.8) Male 4 5.0 nc (nc-nc)
Male 6 10.3 58.0 (21.2-126.3) Male 6 7.3 81.7 (29.8-177.7)Female 5 7.4 67.2 (21.7-156.8) Female 27 21.8 123.9 (81.6-180.2)
Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOSMale 10 9.1 110.0 (52.7-202.4)
Female 1 2.7 nc (nc-nc) Female 21 22.9 91.7 (56.8-140.2)Lung and Bronchus All Sites / Types
Male 45 42.9 105.0 (76.6-140.5) Male 347 334.5 103.7 (93.1-115.2)Female 47 43.8 107.4 (78.9-142.8) Female 342 339.8 100.7 (90.3-111.9)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
220
North BrookfieldObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 2 4.3 nc (nc-nc) Male 4 3.0 nc (nc-nc)Female 1 1.8 nc (nc-nc) Female 1 2.6 nc (nc-nc)
Brain and Other Nervous System Multiple MyelomaMale 2 1.0 nc (nc-nc) Male 0 0.9 nc (nc-nc)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
221
North ReadingObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 11 14.4 76.5 (38.1-136.9) Male 16 9.8 163.0 (93.1-264.8)Female 8 5.2 153.9 (66.3-303.4) Female 13 8.1 160.7 (85.5-274.8)
Brain and Other Nervous System Multiple MyelomaMale 5 3.1 160.3 (51.6-374.0) Male 4 3.1 nc (nc-nc)
Male 12 6.0 198.5 (102.4-346.7) Male 4 4.3 nc (nc-nc)Female 7 4.3 162.0 (64.9-333.7) Female 16 12.5 128.1 (73.2-208.0)
Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOSMale 4 5.5 nc (nc-nc)
Female 3 1.7 nc (nc-nc) Female 18 14.7 122.4 (72.5-193.5)Lung and Bronchus All Sites / Types
Male 19 26.5 71.7 (43.1-112.0) Male 201 203.6 98.7 (85.5-113.4)Female 23 29.0 79.3 (50.2-118.9) Female 214 211.9 101.0 (87.9-115.5)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
222
NorthamptonObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 32 29.4 108.7 (74.3-153.5) Male 12 18.8 63.7 (32.9-111.3)Female 10 11.1 90.1 (43.1-165.7) Female 12 16.1 74.4 (38.4-130.0)
Brain and Other Nervous System Multiple MyelomaMale 6 5.5 108.4 (39.6-235.9) Male 1 6.0 nc (nc-nc)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
223
NorthboroughObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 20 15.2 132.0 (80.6-203.9) Male 9 9.9 91.0 (41.5-172.7)Female 9 5.4 166.5 (76.0-316.1) Female 6 7.7 78.1 (28.5-170.0)
Brain and Other Nervous System Multiple MyelomaMale 0 3.0 nc (nc-nc) Male 4 3.1 nc (nc-nc)
Male 12 6.2 193.7 (100.0-338.4) Male 2 3.9 nc (nc-nc)Female 3 4.5 nc (nc-nc) Female 8 11.0 72.4 (31.2-142.7)
Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOSMale 3 5.4 nc (nc-nc)
Female 1 1.7 nc (nc-nc) Female 21 13.3 157.7 (97.6-241.0)Lung and Bronchus All Sites / Types
Male 16 26.8 59.8 (34.1-97.1) Male 172 201.7 85.3 (73.0-99.0)Female 18 27.5 65.6 (38.8-103.6) Female 196 202.5 96.8 (83.7-111.3)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
224
NorthbridgeObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 22 15.8 138.8 (87.0-210.2) Male 8 10.4 77.2 (33.2-152.0)Female 8 5.3 150.8 (64.9-297.1) Female 9 8.1 111.5 (50.9-211.7)
Brain and Other Nervous System Multiple MyelomaMale 0 3.2 nc (nc-nc) Male 8 3.3 245.6 (105.8-484.0)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
225
NorthfieldObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 3 4.2 nc (nc-nc) Male 2 2.7 nc (nc-nc)Female 1 1.2 nc (nc-nc) Female 3 1.7 nc (nc-nc)
Brain and Other Nervous System Multiple MyelomaMale 0 0.8 nc (nc-nc) Male 1 0.9 nc (nc-nc)
Female 2 0.9 nc (nc-nc) Female 2 2.5 nc (nc-nc)Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOS
Male 0 1.4 nc (nc-nc)
Female 1 0.4 nc (nc-nc) Female 4 3.3 nc (nc-nc)Lung and Bronchus All Sites / Types
Male 3 7.6 nc (nc-nc) Male 33 56.4 58.5 (40.2-82.1)Female 4 6.5 nc (nc-nc) Female 38 46.1 82.5 (58.4-113.2)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
226
NortonObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 10 16.8 59.4 (28.5-109.3) Male 14 11.5 121.3 (66.3-203.6)Female 8 6.3 127.4 (54.9-251.1) Female 15 9.7 155.2 (86.8-255.9)
Brain and Other Nervous System Multiple MyelomaMale 5 3.7 135.3 (43.6-315.6) Male 1 3.6 nc (nc-nc)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
227
NorwellObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 11 12.9 85.6 (42.7-153.1) Male 5 8.1 61.7 (19.9-144.1)Female 2 4.6 nc (nc-nc) Female 14 6.1 229.3 (125.3-384.8)
Brain and Other Nervous System Multiple MyelomaMale 6 2.4 250.3 (91.4-544.8) Male 1 2.6 nc (nc-nc)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
228
NorwoodObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 14 34.0 41.1 (22.5-69.0) Male 33 21.5 153.5 (105.7-215.6)Female 13 12.3 105.4 (56.0-180.2) Female 25 16.4 152.4 (98.6-225.0)
Brain and Other Nervous System Multiple MyelomaMale 10 6.3 159.6 (76.4-293.5) Male 8 6.8 117.2 (50.5-231.0)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
229
Oak BluffsObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 8 6.9 115.8 (49.9-228.3) Male 10 4.3 233.9 (112.0-430.2)Female 0 2.4 nc (nc-nc) Female 2 2.8 nc (nc-nc)
Brain and Other Nervous System Multiple MyelomaMale 0 1.1 nc (nc-nc) Male 0 1.4 nc (nc-nc)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
230
OakhamObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 1 2.2 nc (nc-nc) Male 0 1.4 nc (nc-nc)Female 1 0.6 nc (nc-nc) Female 1 1.0 nc (nc-nc)
Brain and Other Nervous System Multiple MyelomaMale 1 0.4 nc (nc-nc) Male 0 0.5 nc (nc-nc)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
231
OrangeObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 5 9.3 53.6 (17.3-125.0) Male 2 6.0 nc (nc-nc)Female 2 3.1 nc (nc-nc) Female 2 4.3 nc (nc-nc)
Brain and Other Nervous System Multiple MyelomaMale 3 1.8 nc (nc-nc) Male 0 1.9 nc (nc-nc)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
232
OrleansObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CI
Bladder, Urinary Melanoma of SkinMale 14 15.7 89.0 (48.6-149.3) Male 19 8.7 218.4 (131.4-341.1)
Female 7 5.2 133.5 (53.5-275.1) Female 10 5.6 178.9 (85.6-329.0)Brain and Other Nervous System Multiple Myeloma
Male 2 2.0 nc (nc-nc) Male 3 2.9 nc (nc-nc)Female 2 1.7 nc (nc-nc) Female 1 2.3 nc (nc-nc)
Breast Non-Hodgkin LymphomaMale 0 0.5 nc (nc-nc) Male 10 7.5 132.7 (63.5-244.1)
Male 7 5.2 133.5 (53.5-275.1) Male 1 2.2 nc (nc-nc)Female 2 3.6 nc (nc-nc) Female 3 5.7 nc (nc-nc)
Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOSMale 4 4.3 nc (nc-nc)
Female 1 1.6 nc (nc-nc) Female 13 11.3 114.9 (61.1-196.5)Lung and Bronchus All Sites / Types
Male 12 28.3 42.5 (21.9-74.2) Male 144 181.2 79.5 (67.0-93.6)Female 18 28.0 64.4 (38.1-101.8) Female 183 168.0 108.9 (93.7-125.9)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
233
OtisObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 1 2.8 nc (nc-nc) Male 2 1.7 nc (nc-nc)Female 0 0.6 nc (nc-nc) Female 1 0.9 nc (nc-nc)
Brain and Other Nervous System Multiple MyelomaMale 0 0.4 nc (nc-nc) Male 0 0.6 nc (nc-nc)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
234
OxfordObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 20 11.0 181.7 (111.0-280.7) Male 12 7.9 151.7 (78.3-265.0)Female 7 4.5 156.1 (62.5-321.7) Female 6 7.0 85.3 (31.2-185.7)
Brain and Other Nervous System Multiple MyelomaMale 3 2.7 nc (nc-nc) Male 5 2.4 207.4 (66.8-484.0)
Female 0 2.2 nc (nc-nc) Female 3 2.1 nc (nc-nc)
Breast Non-Hodgkin LymphomaMale 0 0.4 nc (nc-nc) Male 8 7.1 112.4 (48.4-221.5)
Male 10 5.0 201.3 (96.4-370.3) Male 6 3.6 165.1 (60.3-359.4)Female 7 3.9 181.6 (72.8-374.3) Female 16 10.9 146.5 (83.7-237.9)
Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOSMale 7 4.4 159.0 (63.7-327.6)
Female 1 1.5 nc (nc-nc) Female 19 12.2 155.9 (93.8-243.5)Lung and Bronchus All Sites / Types
Male 37 20.4 181.8 (128.0-250.6) Male 200 160.6 124.6 (107.9-143.1)Female 34 23.7 143.3 (99.2-200.2) Female 222 180.0 123.3 (107.6-140.6)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
235
PalmerObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 18 11.9 150.6 (89.2-238.1) Male 11 8.2 134.0 (66.8-239.7)Female 9 5.6 161.8 (73.8-307.1) Female 8 7.3 110.3 (47.5-217.3)
Brain and Other Nervous System Multiple MyelomaMale 6 2.5 237.3 (86.6-516.4) Male 0 2.6 nc (nc-nc)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
236
PaxtonObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 4 5.9 nc (nc-nc) Male 6 3.7 162.4 (59.3-353.4)Female 1 1.8 nc (nc-nc) Female 2 2.5 nc (nc-nc)
Brain and Other Nervous System Multiple MyelomaMale 2 1.1 nc (nc-nc) Male 2 1.2 nc (nc-nc)
Male 4 2.3 nc (nc-nc) Male 2 1.3 nc (nc-nc)Female 2 1.4 nc (nc-nc) Female 3 3.5 nc (nc-nc)
Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOSMale 2 2.0 nc (nc-nc)
Female 1 0.6 nc (nc-nc) Female 4 4.8 nc (nc-nc)Lung and Bronchus All Sites / Types
Male 7 10.7 65.7 (26.3-135.3) Male 75 75.5 99.3 (78.1-124.5)Female 6 9.4 63.6 (23.2-138.5) Female 61 66.8 91.4 (69.9-117.4)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
237
PeabodyObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 87 72.3 120.4 (96.4-148.5) Male 38 43.0 88.4 (62.6-121.4)Female 36 27.9 129.1 (90.4-178.8) Female 33 34.4 96.1 (66.1-134.9)
Brain and Other Nervous System Multiple MyelomaMale 10 11.7 85.2 (40.8-156.6) Male 21 13.7 152.8 (94.6-233.6)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
238
PelhamObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 2 1.9 nc (nc-nc) Male 0 1.2 nc (nc-nc)Female 0 0.7 nc (nc-nc) Female 2 0.9 nc (nc-nc)
Brain and Other Nervous System Multiple MyelomaMale 0 0.3 nc (nc-nc) Male 0 0.4 nc (nc-nc)
Male 0 0.7 nc (nc-nc) Male 1 0.4 nc (nc-nc)Female 0 0.5 nc (nc-nc) Female 0 1.2 nc (nc-nc)
Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOSMale 0 0.7 nc (nc-nc)
Female 0 0.2 nc (nc-nc) Female 1 1.8 nc (nc-nc)Lung and Bronchus All Sites / Types
Male 0 3.5 nc (nc-nc) Male 12 25.8 46.4 (24.0-81.1)Female 0 3.7 nc (nc-nc) Female 10 25.3 39.6 (18.9-72.8)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
239
PembrokeObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 21 16.2 129.5 (80.1-197.9) Male 12 11.1 108.1 (55.8-188.8)Female 8 5.4 148.6 (64.0-292.8) Female 13 9.0 143.7 (76.5-245.8)
Brain and Other Nervous System Multiple MyelomaMale 1 3.5 nc (nc-nc) Male 2 3.5 nc (nc-nc)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
240
PepperellObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 5 10.5 47.4 (15.3-110.7) Male 8 7.5 107.1 (46.1-211.0)Female 3 3.4 nc (nc-nc) Female 3 5.8 nc (nc-nc)
Brain and Other Nervous System Multiple MyelomaMale 3 2.4 nc (nc-nc) Male 2 2.4 nc (nc-nc)
Male 5 4.6 109.8 (35.4-256.2) Male 7 3.4 208.3 (83.4-429.1)Female 4 2.9 nc (nc-nc) Female 7 9.4 74.7 (29.9-153.9)
Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOSMale 1 4.5 nc (nc-nc)
Female 0 1.2 nc (nc-nc) Female 15 11.1 135.2 (75.6-223.0)Lung and Bronchus All Sites / Types
Male 22 19.7 111.5 (69.8-168.8) Male 141 156.8 89.9 (75.7-106.1)Female 19 19.5 97.5 (58.7-152.3) Female 156 148.6 105.0 (89.1-122.8)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
241
PeruObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 0 0.6 nc (nc-nc) Male 1 0.5 nc (nc-nc)Female 0 0.2 nc (nc-nc) Female 0 0.4 nc (nc-nc)
Brain and Other Nervous System Multiple MyelomaMale 0 0.2 nc (nc-nc) Male 0 0.2 nc (nc-nc)
Lung and Bronchus All Sites / TypesMale 1 1.2 nc (nc-nc) Male 11 10.2 108.2 (53.9-193.6)
Female 0 1.1 nc (nc-nc) Female 3 9.7 nc (nc-nc)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
242
PetershamObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 2 1.7 nc (nc-nc) Male 0 1.0 nc (nc-nc)Female 0 0.8 nc (nc-nc) Female 0 0.9 nc (nc-nc)
Brain and Other Nervous System Multiple MyelomaMale 0 0.3 nc (nc-nc) Male 1 0.3 nc (nc-nc)
Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOSMale 1 0.5 nc (nc-nc)
Female 1 0.2 nc (nc-nc) Female 2 1.6 nc (nc-nc)Lung and Bronchus All Sites / Types
Male 4 2.8 nc (nc-nc) Male 13 21.0 61.9 (32.9-105.9)Female 0 3.7 nc (nc-nc) Female 14 25.2 55.5 (30.3-93.1)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
243
PhillipstonObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 3 1.6 nc (nc-nc) Male 0 1.1 nc (nc-nc)Female 0 0.5 nc (nc-nc) Female 1 0.8 nc (nc-nc)
Brain and Other Nervous System Multiple MyelomaMale 0 0.4 nc (nc-nc) Male 0 0.4 nc (nc-nc)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
244
PittsfieldObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 62 54.6 113.5 (87.0-145.5) Male 31 33.8 91.8 (62.3-130.3)Female 26 22.3 116.8 (76.3-171.1) Female 28 28.6 97.9 (65.0-141.5)
Brain and Other Nervous System Multiple MyelomaMale 14 9.6 145.4 (79.4-244.0) Male 9 10.7 83.8 (38.2-159.0)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
245
PlainfieldObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 0 1.1 nc (nc-nc) Male 1 0.7 nc (nc-nc)Female 0 0.3 nc (nc-nc) Female 1 0.4 nc (nc-nc)
Brain and Other Nervous System Multiple MyelomaMale 0 0.2 nc (nc-nc) Male 0 0.2 nc (nc-nc)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
246
PlainvilleObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 13 7.1 182.4 (97.0-311.9) Male 5 5.0 100.2 (32.3-233.7)Female 2 3.0 nc (nc-nc) Female 4 4.5 nc (nc-nc)
Brain and Other Nervous System Multiple MyelomaMale 2 1.6 nc (nc-nc) Male 2 1.5 nc (nc-nc)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
247
PlymouthObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 71 65.2 108.9 (85.0-137.3) Male 65 42.6 152.5 (117.7-194.4)Female 19 22.9 82.8 (49.8-129.3) Female 61 32.3 188.6 (144.2-242.3)
Brain and Other Nervous System Multiple MyelomaMale 11 12.7 86.7 (43.2-155.1) Male 9 13.4 67.1 (30.6-127.3)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
248
PlymptonObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 4 3.3 nc (nc-nc) Male 2 2.2 nc (nc-nc)Female 1 0.9 nc (nc-nc) Female 2 1.5 nc (nc-nc)
Brain and Other Nervous System Multiple MyelomaMale 2 0.6 nc (nc-nc) Male 0 0.7 nc (nc-nc)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
249
PrincetonObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 5 3.3 150.3 (48.4-350.8) Male 4 2.4 nc (nc-nc)Female 0 1.0 nc (nc-nc) Female 3 1.7 nc (nc-nc)
Brain and Other Nervous System Multiple MyelomaMale 4 0.8 nc (nc-nc) Male 0 0.7 nc (nc-nc)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
250
ProvincetownObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CI
Bladder, Urinary Melanoma of SkinMale 1 4.9 nc (nc-nc) Male 7 3.3 214.1 (85.8-441.1)
Female 4 1.6 nc (nc-nc) Female 3 2.0 nc (nc-nc)Brain and Other Nervous System Multiple Myeloma
Male 1 0.9 nc (nc-nc) Male 0 1.1 nc (nc-nc)Female 1 0.6 nc (nc-nc) Female 1 0.7 nc (nc-nc)
Breast Non-Hodgkin LymphomaMale 0 0.2 nc (nc-nc) Male 4 2.9 nc (nc-nc)
Male 0 1.9 nc (nc-nc) Male 1 1.3 nc (nc-nc)Female 2 1.2 nc (nc-nc) Female 2 2.4 nc (nc-nc)
Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOSMale 3 2.0 nc (nc-nc)
Female 1 0.5 nc (nc-nc) Female 2 4.0 nc (nc-nc)Lung and Bronchus All Sites / Types
Male 12 9.1 132.0 (68.1-230.7) Male 79 69.3 113.9 (90.2-142.0)Female 14 8.3 168.7 (92.2-283.1) Female 72 56.5 127.4 (99.7-160.5)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
251
QuincyObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 91 97.3 93.5 (75.3-114.8) Male 51 62.8 81.2 (60.4-106.7)Female 31 36.7 84.6 (57.5-120.0) Female 56 52.6 106.5 (80.4-138.3)
Brain and Other Nervous System Multiple MyelomaMale 18 18.8 95.6 (56.6-151.1) Male 18 19.4 92.6 (54.8-146.3)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
252
RandolphObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 35 34.2 102.2 (71.2-142.2) Male 17 21.9 77.6 (45.2-124.2)Female 7 12.7 55.1 (22.1-113.5) Female 16 18.6 86.3 (49.3-140.1)
Brain and Other Nervous System Multiple MyelomaMale 6 6.5 92.8 (33.9-201.9) Male 7 6.9 101.3 (40.6-208.7)
Male 10 13.6 73.7 (35.3-135.6) Male 9 8.4 107.3 (49.0-203.8)Female 3 10.6 nc (nc-nc) Female 33 27.4 120.5 (82.9-169.2)
Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOSMale 16 11.6 138.3 (79.0-224.6)
Female 3 4.1 nc (nc-nc) Female 29 32.6 88.8 (59.5-127.6)Lung and Bronchus All Sites / Types
Male 46 60.7 75.8 (55.5-101.1) Male 401 441.0 90.9 (82.2-100.3)Female 56 66.9 83.7 (63.2-108.7) Female 428 486.2 88.0 (79.9-96.8)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
253
RaynhamObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 16 13.7 116.6 (66.6-189.4) Male 4 9.1 nc (nc-nc)Female 7 5.1 137.7 (55.2-283.8) Female 9 7.2 124.4 (56.7-236.1)
Brain and Other Nervous System Multiple MyelomaMale 3 2.8 nc (nc-nc) Male 3 2.8 nc (nc-nc)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
254
ReadingObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 36 26.0 138.4 (96.9-191.7) Male 18 16.9 106.3 (62.9-168.0)Female 6 10.5 57.3 (20.9-124.7) Female 13 14.2 91.3 (48.5-156.1)
Brain and Other Nervous System Multiple MyelomaMale 5 5.2 96.7 (31.1-225.6) Male 5 5.3 93.9 (30.3-219.1)
Male 11 10.6 103.8 (51.8-185.8) Male 8 6.6 120.7 (52.0-237.8)Female 11 8.4 130.5 (65.0-233.4) Female 28 20.0 140.2 (93.2-202.7)
Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOSMale 9 9.1 98.8 (45.1-187.5)
Female 5 3.3 153.8 (49.6-358.9) Female 28 25.1 111.4 (74.0-161.0)Lung and Bronchus All Sites / Types
Male 42 46.9 89.5 (64.5-121.0) Male 311 344.4 90.3 (80.6-100.9)Female 47 54.0 87.1 (64.0-115.8) Female 395 382.0 103.4 (93.4-114.1)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
255
RehobothObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 10 12.5 80.0 (38.3-147.1) Male 10 8.4 118.8 (56.9-218.5)Female 3 3.6 nc (nc-nc) Female 4 5.8 nc (nc-nc)
Brain and Other Nervous System Multiple MyelomaMale 0 2.6 nc (nc-nc) Male 2 2.7 nc (nc-nc)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
256
RevereObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 50 47.8 104.6 (77.7-138.0) Male 23 32.5 70.8 (44.8-106.2)Female 16 19.7 81.2 (46.4-131.8) Female 27 28.3 95.5 (62.9-139.0)
Brain and Other Nervous System Multiple MyelomaMale 11 10.3 106.7 (53.2-190.9) Male 6 9.8 61.2 (22.3-133.2)
Male 31 20.3 152.7 (103.7-216.8) Male 11 13.9 79.4 (39.6-142.1)Female 11 16.2 68.0 (33.9-121.7) Female 44 41.2 106.9 (77.7-143.5)
Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOSMale 27 16.9 160.0 (105.4-232.8)
Female 6 6.2 96.9 (35.4-210.9) Female 35 47.7 73.3 (51.1-102.0)Lung and Bronchus All Sites / Types
Male 127 85.0 149.4 (124.6-177.8) Male 683 642.7 106.3 (98.5-114.6)Female 139 103.2 134.7 (113.2-159.0) Female 742 733.0 101.2 (94.1-108.8)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
257
RichmondObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 0 3.0 nc (nc-nc) Male 2 1.7 nc (nc-nc)Female 1 0.9 nc (nc-nc) Female 1 1.1 nc (nc-nc)
Brain and Other Nervous System Multiple MyelomaMale 0 0.4 nc (nc-nc) Male 0 0.6 nc (nc-nc)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
258
RochesterObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 2 6.0 nc (nc-nc) Male 5 3.9 127.6 (41.1-297.8)Female 4 2.1 nc (nc-nc) Female 3 3.0 nc (nc-nc)
Brain and Other Nervous System Multiple MyelomaMale 0 1.2 nc (nc-nc) Male 1 1.3 nc (nc-nc)
Male 2 2.4 nc (nc-nc) Male 1 1.6 nc (nc-nc)Female 1 1.7 nc (nc-nc) Female 2 4.3 nc (nc-nc)
Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOSMale 2 2.2 nc (nc-nc)
Female 0 0.7 nc (nc-nc) Female 3 5.7 nc (nc-nc)Lung and Bronchus All Sites / Types
Male 13 11.0 117.7 (62.6-201.3) Male 78 82.4 94.7 (74.8-118.2)Female 3 10.7 nc (nc-nc) Female 65 80.2 81.1 (62.6-103.3)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
259
RocklandObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 21 17.6 119.0 (73.6-181.9) Male 15 11.8 127.1 (71.1-209.7)Female 11 7.2 152.7 (76.1-273.2) Female 17 10.0 169.3 (98.5-271.0)
Brain and Other Nervous System Multiple MyelomaMale 6 3.6 164.9 (60.2-359.0) Male 3 3.6 nc (nc-nc)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
260
RockportObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 12 12.4 97.1 (50.1-169.6) Male 10 7.3 136.7 (65.4-251.4)Female 2 4.7 nc (nc-nc) Female 7 5.5 127.6 (51.1-262.9)
Brain and Other Nervous System Multiple MyelomaMale 2 1.9 nc (nc-nc) Male 1 2.4 nc (nc-nc)
Liver and Intrahepatic Bile Ducts Uteri Corpus and Uterus, NOSMale 2 4.0 nc (nc-nc)
Female 1 1.4 nc (nc-nc) Female 7 10.2 68.9 (27.6-142.0)Lung and Bronchus All Sites / Types
Male 17 22.1 77.0 (44.8-123.2) Male 139 151.8 91.6 (77.0-108.1)Female 7 23.7 29.5 (11.8-60.8) Female 128 156.2 82.0 (68.4-97.5)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
261
RoweObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 2 0.9 nc (nc-nc) Male 1 0.5 nc (nc-nc)Female 0 0.2 nc (nc-nc) Female 1 0.3 nc (nc-nc)
Brain and Other Nervous System Multiple MyelomaMale 0 0.1 nc (nc-nc) Male 0 0.2 nc (nc-nc)
Lung and Bronchus All Sites / TypesMale 0 1.6 nc (nc-nc) Male 7 10.7 65.2 (26.1-134.4)
Female 0 1.1 nc (nc-nc) Female 4 7.7 nc (nc-nc)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
262
RowleyObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 7 5.5 128.4 (51.4-264.6) Male 4 3.9 nc (nc-nc)Female 2 2.1 nc (nc-nc) Female 6 3.4 178.9 (65.3-389.5)
Brain and Other Nervous System Multiple MyelomaMale 1 1.2 nc (nc-nc) Male 2 1.2 nc (nc-nc)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;
263
RoyalstonObserved and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013
Obs Exp SIR 95% CI Obs Exp SIR 95% CIBladder, Urinary Melanoma of Skin
Male 0 1.3 nc (nc-nc) Male 0 0.9 nc (nc-nc)Female 2 0.4 nc (nc-nc) Female 0 0.6 nc (nc-nc)
Brain and Other Nervous System Multiple MyelomaMale 0 0.3 nc (nc-nc) Male 0 0.3 nc (nc-nc)
Obs = observed case count; Exp = expected case count; SIR = standardized incidence ratio ( (Obs / Exp) X 100); 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability; nc = The SIR and 95% CI were not calculated when Obs < 5;